Linagliptin/Metformin Sandoz

Linagliptin and Metformin Hydrochloride, the active ingredient in Linagliptin/Metformin Sandoz, is a DPP‑4 inhibitor; biguanide presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus as an adjunct to diet and exercise. GNH USA supplies Linagliptin/Metformin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin/Metformin Sandoz is used in the treatment of type 2 diabetes and related glycaemic control pathways. - Type 2 diabetes mellitus: improves overall glycaemic control when added to diet and exercise. - Inadequate control on metformin alone: provides additional glucose‑lowering effect. - Patients requiring combination therapy: offers a fixed‑dose option to simplify regimens.

The following adverse reactions have been reported with Linagliptin/Metformin therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: loose stools often occurring early in treatment. - Abdominal discomfort: cramping or pain in the stomach area. - Headache: transient mild headache. - Dizziness: occasional light‑headedness. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Pancreatitis: severe inflammation of the pancreas. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or liver injury. - Renal impairment: worsening kidney function, especially in predisposed patients.

Before prescribing Linagliptin/Metformin, clinicians should consider several safety aspects. - Renal function: assess baseline creatinine clearance and monitor regularly. - Hepatic function: evaluate liver enzymes due to risk of lactic acidosis. - Cardiovascular disease: use with caution in patients with unstable heart conditions. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Drug interactions: review concomitant medications, especially insulin, sulfonylureas, and contrast agents. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Linagliptin/Metformin may interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycaemia. - Intravenous iodinated contrast: discontinue metformin before and after the procedure to prevent renal dysfunction. - Severe renal impairment: metformin accumulation can lead to lactic acidosis.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Beta‑blockers: may mask symptoms of hypoglycaemia. - Alcohol consumption: can increase the risk of lactic acidosis.